
Accumulating evidence indicates that pathological interactions between -synuclein (ASN) and tau contribute to the progression of -synucleinopathies; however, the mechanisms linking ASN exposure to tau dysregulation and neuronal cytoskeletal pathology remain incompletely understood. In the present study, we investigated whether bilateral intrastriatal injection of ASN oligomers induces alterations in tau phosphorylation associated with microtubule (MT) abnormalities in the mouse brain. Western blot analyses were performed in the striatum, midbrain, and cortex at 180 days post-injection to assess tau phosphorylation at disease-associated epitopes (Ser199/202, Ser404, and Ser416) together with / -tubulin levels. Ultrastructural changes in neuronal cytoskeletal organisation were evaluated qualitatively using transmission electron microscopy (TEM). ASN exposure induced selective, bidirectional, site- and region-specific changes in tau phosphorylation rather than uniform hyperphosphorylation. Increased p-tau(Ser199/202) levels were observed in the striatum and cortex, whereas p-tau(Ser404) was elevated in the midbrain but decreased in the cortex. No significant changes in p-tau(Ser416) or / -tubulin levels were detected in any analysed brain region. TEM analyses further revealed disrupted neuronal MT organisation, characterised by fragmented and loosely packed MT networks, reduced MT abundance, and occasional loss of cytoskeletal elements accompanied by axonal or synaptic swelling, despite preserved total / -tubulin levels. Collectively, our findings indicate that ASN oligomers induce selective, region-specific dysregulation of tau phosphorylation that co-occurs with neuronal MT disorganisation and cytoskeletal abnormalities. Together, these findings support a link between ASN-induced, site- and region-specific tau dysregulation and neuronal cytoskeletal pathology in -synucleinopathies.
INTRODUCTION:Glucocorticoid therapy is commonly used in inflammatory myopathies (IMs); however, patients' responses are variable, and predictive biomarkers remain unavailable. 11 -hydroxysteroid dehydrogenase type 1 (11 -HSD1), a key enzyme regulating intracellular glucocorticoid activation, may influence treatment response. This study evaluated the relationship between muscle 11 -HSD1 expression and clinical response to glucocorticoid therapy. MATERIAL AND METHODS:This study included 32 patients with biopsy-confirmed IMs, of whom 25 received post-biopsy prednisolone (0.5-1 mg/kg/day) for approximately 8 months without glucocorticoid-sparing agents. Clinical response was evaluated based on muscle strength, symptom improvement, and creatinine kinase (CK) reduction. Muscle 11 -HSD1 expression was assessed and categorized as low-medium or high. Associations between enzyme expression and response to glucocorticoid were analyzed. Receiver operating characteristic (ROC) curve analysis was performed to assess the predictive performance of 11 -HSD1 expression. RESULTS:Among the 25 treated patients with glucocorticoid therapy, 21 (84.0%) demonstrated clinical improvement, while 4 (16.0%) showed no clinical response. Baseline diagnostic subtypes and MHC class I expression were not significantly associated with treatment outcome (p = 0.37 and p = 0.59, respectively). In contrast, high 11 -HSD1 expression was significantly associated with clinical improvement (66.7% vs. 0% in non-responders; p = 0.026). High 11 -HSD1 expression was associated with increased odds of response (OR = 17.4, 95% CI: 0.77-392). ROC analysis demonstrated good predictive performance (AUC = 0.83). CONCLUSIONS:Elevated muscle 11 -HSD1 expression before glucocorticoid therapy was associated with an improved clinical response after therapy in IMs. These findings support the potential role of 11 -HSD1 as a predictive biomarker.
INTRODUCTION:Accurately stratifying the risk of poor outcomes after acute ischaemic stroke remains a critical challenge. Complete blood count (CBC)-derived indices, such as the neutrophil-to-lymphocyte ratio (NLR), have been proposed as prognostic markers. However, their performance compared to other recently proposed CBC-based parameters, including the derived neutrophil-to-lymphocyte ratio (dNLR) and neutrophil-to-lymphocyte-and-platelet ratio (NLPR), remains unclear. MATERIAL AND METHODS:A retrospective analysis of records from 202 patients with acute ischaemic stroke treated with intravenous thrombolysis (IVT) was performed. NLR, dNLR, NLPR and six other novel inflammatory indices - lymphocyte-to-monocyte ratio (LMR), platelet-to-lymphocyte ratio (PLR), mean platelet volume to platelet count ratio (MPR), systemic inflammatory index (SII), systemic inflammation response index (SIRI), and aggregate index of systemic inflammation (AISI) - were calculated from the CBC acquired upon admission and one day after IVT. Differences in laboratory parameters and ratios between groups of diverse outcomes were tested, and diagnostic performance between ratios was compared using multivariate logistic regression models. RESULTS:Three inflammatory ratios (NLR, dNLR, NLPR) measured the day after IVT were found to be independent risk factors for a poor functional outcome at discharge. The upper quartile of NLR and dNLR alone presented similar performance (OR = 4.04, 95% CI: 2.06-7.92, p < 0.001; sensitivity 40%, specificity 86%, AUC = 0.63). However, dNLR showed higher discrimination value in the combined model with pre-mRS and NIHSS (OR = 5.50, 95% CI: 2.02-14.93, p < 0.001; sensitivity 81%, specificity 93%, AUC = 0.929). This parameter, along with glucose levels, was also associated with the risk of early intracranial bleeding (OR = 4.74, 95% CI: 1.24-18.21, p = 0.023). CONCLUSIONS:In this exploratory study, dNLR measured on the day after IVT was superior to NLR and other parameters in prognosis of unfavourable outcomes and recognition of intracranial haemorrhage. Nevertheless, clinical data such as pre-mRS and NIHSS combined remain the most important predictors.
INTRODUCTION:It has been reported that neonatal encephalopathy (NE) with early-onset sepsis (EOS) may have worse outcomes in comparison to non-septic NE. The aim of this study was to evaluate the association of EOS and short-term adverse outcomes of NE. MATERIAL AND METHODS:This retrospective observational study evaluated the short-term outcomes of NE patients with and without EOS at the The Affiliated Hospital of Yangzhou University Medical College Hospital between July 2021 and July 2024. Eighty-seven patients with mild NE were included in the study, 21 of whom also had EOS (EOSNE group) and 66 of whom did not have EOS (NE group), and these two groups were used to compare the short-term outcomes. RESULTS:Abnormal neurological examinations were found in 42.9% of the EOSNE group vs. 19.7% of the NE group, which was significantly higher in the EOSNE group (p = 0.03). The seizure rate until discharge day in the EOSNE group was 38.1% vs. 15.2% in the NE group, which was significantly higher in the EOSNE group (p = 0.02). Abnormal electroencephalogram (EEG) findings were observed in 47.6% of the EOSNE group vs. 15.2% of the NE group (p = 0.004). Also, 47.6% of the EOSNE group vs. 15.2% in the NE group used antiplatelet medications until discharge day, which was significantly higher in the EOSNE group (p = 0.004). The proportion of patients receiving blood products was significantly higher in the EOSNE group (57.1% vs. 15.2% p = 0.001). CONCLUSIONS:The rate of hospitalization in EOSNE patients was higher than in NE patients. Abnormal neurological examinations, abnormal EEG, seizures, receipt of blood products, and use of antiepileptic drugs were more common in these patients.
INTRODUCTION:Glioma constitutes approximately 50% of primary brain tumors. This study aimed to analyze the mechanism by which TRIM38 contributes to the progression of glioma. MATERIAL AND METHODS:The LN229 and T98G glioma cell lines were purchased. To evaluate cell malignant behaviors, Cell Counting Kit-8 (CCK-8) and Transwell assays were employed. Levels of TRIM38 and IkBa were quantified by RT-qPCR and Western blotting, respectively. Co-immunoprecipitation analyses were conducted to investigate the relationship between TRIM38 and IkBa. RESULTS:The findings demonstrated that TRIM38 was overexpressed in LN229 and T98G glioma cell lines. The silencing of TRIM38 inhibited malignant behaviors, whereas overexpression of TRIM38 had a stimulatory effect on these processes. Moreover, TRIM38 knockdown suppressed glioma growth in vivo. Co-immunoprecipitation assays confirmed that TRIM38 could bind to IkBa. Notably, TRIM38 increased the ubiquitination of IkBa, leading to its protein degradation and subsequent enhancement of IkBa phosphorylation, which activated the NF-kB pathway. JSH-23 treatment counteracted TRIM38 roles in glioma cells. CONCLUSIONS:In summary, high levels of TRIM38 promoted glioma progression by increasing the ubiquitination of IkBa, thereby reducing IkBa protein stability and expression, and stimulating IkBa phosphorylation. This ultimately activated the NF-kB pathway, exacerbating the malignant behavior of glioma cells.